



A Research-based *human health care* Company



Our *human health care* (hhc) Mission

Eisai's commitment to the health and well being of people worldwide is embodied in our *human health care* (hhc) concept. To achieve this, every employee is encouraged to spend time with patients and their families to see the situation from their perspective in order to better empathize with thoughts and feelings that might not necessarily be expressed in words.

These insights give us an understanding of people's unique experiences, challenges and emotions, which drives us to boldly push past the boundaries of science, with the aim of effectively achieving social good in the form of relieving anxiety over health and reducing health care barriers. **Our hhc mission means putting patients and their families at the heart of everything we do.**



"The primary focus of health care must always be the patient, the patient's family, and from a general vantage point, the public as a whole. These are the people we must serve."

Haruo Naito
Global CEO, Eisai Inc., Ltd

Pharmaceutical Business

Eisai, which focuses in the areas of **Neurology** and **Oncology**, has comprehensive biopharmaceutical capabilities from early-stage research and development through final product manufacturing, commercial, global logistics and supply chain.



At the forefront of Alzheimer's disease (AD) research for more than four decades, we are continuing to advance treatments and take steps towards personalized interventions.



We let the science lead us to new approaches that accelerate progress in oncology, even when it takes us to places others refuse to go... especially when it means pursuing breakthroughs in challenging areas unexplored by other companies.



Research & Development

The company annually invests approximately 23% of its consolidated revenues into R&D. Eisai currently has 9 compounds in clinical development (Phase II or later), which are being evaluated in 17 indications.*

Collaboration

Eisai has a proven track record of successful collaborations. Current collaborators include Fortune 500, global biopharma, and global pharmaceutical companies.

* As of February 2025

Eisai Inc. at a Glance



Tatsuyuki Yasuno
Chairman & CEO, Eisai Inc.
President, Americas Region
Senior Vice President, Eisai Co., Ltd.

2000+
jobs created across
our U.S. locations

155+
advocacy groups & professional
societies supported across
oncology and neurology
disease areas



US Headquarters
Nutley, NJ
Eisai US hhc Center
200 Metro Boulevard
Nutley, NJ 07110

US Research Centers
Cambridge, MA
Eisai Center for Genetics
Guided Dementia Discovery
(G2D2)
Exton, PA

Production & Distribution
Baltimore, MD
Exton, PA
Raleigh, NC

Additional US Offices
Washington, DC
San Francisco, CA
Eisai Innovation Inc. (eii)

Living *human health care*: Serving the Community



As part of our *hhc* mission, we seek to bring benefits to patients beyond the development of new treatments. We collaborate with many stakeholders, which enables us to expand our perspectives and advocate on behalf of patients and healthcare providers. One of Eisai's key patient-centric programs is Magnolia, which was created in 2012 to help meet the evolving needs of patients and their families **Two of the four Magnolia program initiatives include:**

Magnolia Meals at Home® provides meals at no cost to eligible patients and families living with all cancer types.

5,200+
patients enrolled
300+
employee volunteers

5,900+
family members served
155,000+
meals delivered



Meal Train® in partnership with **Magnolia** is an online calendar that aims to optimize the impact of meal delivery to patients and families living with cancer and Alzheimer's disease and dementia.

173,871
meal trains created and
2,307,699
meals organized for patients and
families impacted by cancer

2,696
meal trains created and
16,935
meals organized for patients and
families impacted by dementia



All Magnolia figures as of August 2025.



Educational Initiatives as Part of Our *hhc* Mission

Eisai has developed several educational initiatives in which we partner with patient advocacy groups to reflect the patient's voice. The insights and knowledge that we gain from these partnerships and the people impacted by disease, or anyone who faces barriers to care, provide us with invaluable learnings to incorporate across our business.

Two of our programs include:

Spot Her® was launched in 2021 to help end the silence around endometrial cancer (EC), a type of uterine cancer. The Spot Her initiative aims to empower all people across generations and cultures to speak up, take action, and spot the signs at an early stage, when EC may be more treatable. It was developed in partnership with SHARE Cancer Support (SHARE), Facing Our Risk of Cancer Empowered (FORCE), Black Health Matters (BHM) and Endometrial Cancer Action Network for African-Americans (ECANA), and with support from our awareness partners, the Foundation for Women's Cancer (FWC), Ovarian Cancer Research Alliance (OCRA), GOG Foundation and Patient Empowerment Network (PEN). EC is the most common gynecologic cancer in the U.S., and diagnoses and deaths are particularly on the rise in communities of color.



One Liver to Love was created with one community in mind—for patients and families who are living with and affected by liver cancer. It was developed in collaboration with Blue Faery and Global Liver Institute (GLI), two patient advocacy organizations that provide educational resources and support services to the liver cancer community. Communities of color are disproportionately impacted by liver cancer, with the highest incidence rates in Alaska and Alaska Native community. Our goal is to help provide information, the resources, and a sense of community for anyone impacted by liver cancer.



Magnolia Meals at Home® is sponsored by Eisai Inc. in collaboration with CancerCare, Cancer Support Community and Meals On Wheels America. Magnolia Meals at Home® is a registered trademark of Eisai Inc. MealTrain® in partnership with Magnolia is brought to you by Magnolia in collaboration with CancerCare and Cancer Support Community. MealTrain® is a trademark of Meal Train LLC.

Key Corporate Milestones

- 1987** Eisai creates R&D presence in Andover, MA
- 1992** Adopted current corporate mission and corporate objective to include the realization of *human health care* (hhc)
- 1995** Eisai Inc. is established as a US commercial subsidiary in New Jersey
- 1996** Introduces field sales force
Launches first product (neurology); begins production/packaging operations in US
- 2002** Achieves product sales of \$1 billion
- 2006** Starts oncology franchise
- 2007** Acquires Morphotek Inc. to bolster monoclonal antibody development
- 2008** Acquires MGI Pharma, Inc., including a manufacturing facility in Baltimore, MD
- 2010** Inspired by nature and our *hhc* mission, our scientists develop a cancer treatment derived from a sea sponge compound that showed strong anti-tumor activity
Establishes sales and marketing subsidiary in Canada
- 2011** Establishes sales and marketing subsidiaries in Brazil and Mexico
- 2014** Enters into collaboration with Biogen to develop and commercialize investigational Alzheimer's disease treatments
- 2015** Treatment for Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer approved by U.S. Food and Drug Administration (FDA)
- 2018** Signs strategic collaboration for the worldwide co-development and co-commercialization of cancer agent with Merck
Treatment for unresectable hepatocellular carcinoma (HCC) approved by FDA
- 2019** Opens Eisai Center for Genetics Guided Dementia Discovery (G2D2) with a mission of harnessing the power of human genetics to develop next-generation medicines for Alzheimer's disease and other dementias
- 2021** Treatment for advanced endometrial carcinoma (EC) and advanced renal cell carcinoma (RCC) approved by FDA
- 2022** Eisai Inc. moves into Eisai US hhc Center, a new headquarters in Nutley, NJ, that brought all NJ-based employees together in one workplace with the goal to drive a culture of collaboration and innovation
- 2023** First therapy to slow progression of Alzheimer's disease granted traditional approval by FDA
- 2025** First subcutaneous autoinjector to offer an in-home injection to slow the progression of Alzheimer's disease granted traditional approval by FDA



©2025 Eisai Inc. All rights reserved. US5757 us.eisai.com

